Short Interest in Genfit S.A. (NASDAQ:GNFT) Declines By 40.5%

Genfit S.A. (NASDAQ:GNFT) was the recipient of a large drop in short interest in the month of February. As of February 15th, there was short interest totalling 60,300 shares, a drop of 40.5% from the January 31st total of 101,300 shares. Currently, 0.1% of the company’s stock are sold short. Based on an average trading volume of 8,400 shares, the days-to-cover ratio is presently 7.2 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $13.00 target price on shares of Genfit in a report on Friday, February 7th.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Genfit stock. Millennium Management LLC purchased a new stake in shares of Genfit S.A. (NASDAQ:GNFT) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 166,375 shares of the company’s stock, valued at approximately $611,000. Millennium Management LLC owned about 0.33% of Genfit at the end of the most recent reporting period. 2.24% of the stock is owned by institutional investors.

Genfit Trading Down 2.0 %

Shares of NASDAQ:GNFT traded down $0.07 during trading on Friday, reaching $3.47. 7,808 shares of the company traded hands, compared to its average volume of 8,393. The firm has a fifty day simple moving average of $3.74 and a 200 day simple moving average of $4.40. The company has a current ratio of 3.74, a quick ratio of 3.74 and a debt-to-equity ratio of 0.61. Genfit has a 1-year low of $3.35 and a 1-year high of $6.42.

Genfit Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.